Annual Accounts Receivable
$10.37 M
+$9.82 M+1794.08%
December 31, 2023
Summary
- As of March 12, 2025, CAPR annual accounts receivable is $10.37 million, with the most recent change of +$9.82 million (+1794.08%) on December 31, 2023.
- During the last 3 years, CAPR annual accounts receivable has risen by +$10.37 million (+100.00%).
- CAPR annual accounts receivable is now at all-time high.
Performance
CAPR Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$409.70 K
+$39.70 K+10.73%
September 30, 2024
Summary
- As of March 12, 2025, CAPR quarterly accounts receivable is $409.70 thousand, with the most recent change of +$39.70 thousand (+10.73%) on September 30, 2024.
- Over the past year, CAPR quarterly accounts receivable has increased by +$39.70 thousand (+10.73%).
- CAPR quarterly accounts receivable is now -96.05% below its all-time high of $10.37 million, reached on December 31, 2023.
Performance
CAPR Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CAPR Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +1794.1% | +10.7% |
| 3 y3 years | +100.0% | -25.2% |
| 5 y5 years | - | -25.2% |
CAPR Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +2547.9% | -96.0% | +14.8% |
| 5 y | 5-year | at high | -100.0% | -96.0% | -100.0% |
| alltime | all time | at high | -100.0% | -96.0% | -100.0% |
Capricor Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $409.70 K(+10.7%) |
| Jun 2024 | - | $370.00 K(+0.3%) |
| Mar 2024 | - | $369.00 K(-96.4%) |
| Dec 2023 | $10.37 M(+1794.1%) | $10.37 M(+1794.1%) |
| Sep 2023 | - | $547.60 K(0.0%) |
| Jun 2023 | - | $547.60 K(0.0%) |
| Mar 2023 | - | $547.60 K(0.0%) |
| Dec 2022 | $547.60 K | $547.60 K(0.0%) |
| Sep 2022 | - | $547.60 K(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $547.60 K(+53.4%) |
| Mar 2022 | - | $357.00 K(-8.9%) |
| Dec 2021 | $391.70 K(>+9900.0%) | $391.70 K(+117.4%) |
| Sep 2021 | - | $180.20 K(>+9900.0%) |
| Dec 2020 | $0.00(-100.0%) | $0.00(-100.0%) |
| Jun 2002 | - | $100.00(0.0%) |
| Mar 2002 | - | $100.00(0.0%) |
| Dec 2001 | $100.00(-90.0%) | $100.00 |
| Dec 2000 | $1000.00(>+9900.0%) | - |
| Dec 1999 | $0.00 | - |
FAQ
- What is Capricor Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Capricor Therapeutics?
- What is Capricor Therapeutics annual accounts receivable year-on-year change?
- What is Capricor Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Capricor Therapeutics?
- What is Capricor Therapeutics quarterly accounts receivable year-on-year change?
What is Capricor Therapeutics annual accounts receivable?
The current annual accounts receivable of CAPR is $10.37 M
What is the all time high annual accounts receivable for Capricor Therapeutics?
Capricor Therapeutics all-time high annual accounts receivable is $10.37 M
What is Capricor Therapeutics annual accounts receivable year-on-year change?
Over the past year, CAPR annual accounts receivable has changed by +$9.82 M (+1794.08%)
What is Capricor Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of CAPR is $409.70 K
What is the all time high quarterly accounts receivable for Capricor Therapeutics?
Capricor Therapeutics all-time high quarterly accounts receivable is $10.37 M
What is Capricor Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, CAPR quarterly accounts receivable has changed by +$39.70 K (+10.73%)